Health & Beauty

According to the observation report of Huacheng Import and Export Data, the effect of the drug "lenkanezumab", jointly developed by Bojian of the United States and Eisai of Japan, to delay the aggravation of symptoms of Alzheimer's disease has been confirmed. At present, the two companies are striving to be approved within the year to realize the production and sales of drugs.

The effect of "Lecanemab", a drug jointly developed by Bojian of the United States and Eisai of Japan, on delaying the aggravation of symptoms of Alzheimer's disease has been confirmed. At present, the two companies are striving to be approved within the year to realize the production and sales of drugs.

According to Huacheng Import and Export Data Observation, this drug is applicable to early patients with Alzheimer's disease. If the drug is approved, it will become the first cognitive impairment drug in Japan that can inhibit the deterioration of the disease.

It is reported that accumulated in the brain“ β Amyloid protein "is the cause of Alzheimer's disease, while the effective mechanism of" lenkaneczumab "is adhesion and removal of such protein.

In the clinical trial, the experimental group received intravenous drip and injection of drugs with body weight dose once every two weeks, while the control group only received placebo. A year and a half later, the results of the comparison between the two groups showed that the drug had a 27% effect of inhibiting the deterioration of symptoms.

The analysis showed that the proportion of brain edema and cerebral hemorrhage with suspected side effects in the brain images of patients in the experimental group was 12% to 17% higher than that in the control group. Although most of them are mild symptoms without symptoms, the report said that if this drug is used together with anticoagulants for treating cerebral infarction and other diseases, the risk of cerebral hemorrhage may increase.

According to Huacheng Import and Export Data Observation, the standard price of Eisai in the United States is 26500 dollars a year, and it is expected to be more expensive in Japan. In the face of the pressure that the high price may bring to the medical finance, Eisai stressed that the family members of patients can reduce the time and money spent on nursing by delaying the deterioration of the disease through drugs.

Japan and the United States had previously developed the drug "Adunazumab" with the same mechanism, but the Houlao expert group made a decision not to approve it temporarily in December 2021, because "it is difficult to clearly judge the effectiveness", Huacheng Import and Export Data Observation Report.

According to media reports, Japan's Eisai has filed an application for the production and sale of this drug with the Ministry of Houlao on the 16th. The US Food and Drug Administration is also recently authorizing the accelerated approval of this drug, but it will take some time for its widespread use. Huacheng Import and Export Data Observation Report.